Back to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type — Clinical Trials

MONDO:00063835 active·2 recruitingLast updated: Mar 19, 2026, 6:36 PM

Trial Landscape

Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type has an emerging clinical trial program, driven by drug treatment and biological therapy.

Recruiting

Active Trials

By Approach

Drug Treatment5

Biological Therapy5

Procedure3

1 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Phase 2

Sponsor Types

Academic/Other4NIH1

Trial Locations

United States5 trials

Trials often recruit across multiple countries, so totals exceed the trial count.

5 Trials

Phase 2Recruiting

NCT06834373

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Sponsor:Mayo Clinic

United StatesStarted: Apr 2025Est. completion: Mar 2027Updated: Jan 2026

Phase 2Recruiting

NCT05821088

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Sponsor:David Bond, MD

United StatesStarted: Jun 2023Est. completion: Dec 2026Updated: Nov 2025

Phase 2Active, Not Recruiting

NCT03038672

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2018Est. completion: Oct 2026Updated: Nov 2025

Phase 2Active, Not Recruiting

NCT05507541

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Sponsor:Mayo Clinic

United StatesStarted: Apr 2023Est. completion: Jul 2027Updated: Aug 2025

Phase 2Active, Not Recruiting

NCT05202782

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Sponsor:Northwestern University

United StatesStarted: Mar 2022Est. completion: Oct 2029Updated: Oct 2024

Stay informed about clinical trials for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 19, 2026 at 6:36 PM

Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Trial Locations

5 Trials

Open Trials2

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Active Trials3

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma